Edition:
United Kingdom

Eleven Biotherapeutics Inc (EBIO.OQ)

EBIO.OQ on NASDAQ Stock Exchange Global Market

1.72USD
5:17pm BST
Change (% chg)

$0.10 (+6.17%)
Prev Close
$1.62
Open
$1.68
Day's High
$1.78
Day's Low
$1.64
Volume
493,898
Avg. Vol
228,584
52-wk High
$2.00
52-wk Low
$0.63

Select another date:

Wed, Apr 4 2018

BRIEF-Eleven Biotherapeutics Reports Q4 Loss Per Share $0.22

* ELEVEN BIOTHERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 OPERATING RESULTS AND VICINIUM DEVELOPMENT PROGRESS

BRIEF-Eleven Biotherapeutics To Present Early Data From Bladder Cancer Trial In May

* PRELIMINARY DATA FROM PHASE 3 VISTA TRIAL IN BLADDER CANCER TO BE PRESENTED IN A PLENARY SESSION AT AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING

BRIEF-Eleven Biotherapeutics Announces Pricing Of $10.0 Million Offering Priced At-The-Market

* ELEVEN BIOTHERAPEUTICS ANNOUNCES PRICING OF $10.0 MILLION OFFERING PRICED AT-THE-MARKET

BRIEF-Eleven Biotherapeutics Files For Mixed Shelf Of Upto $150 Mln

* ELEVEN BIOTHERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text: (http://bit.ly/2u2wguN) Further company coverage:

BRIEF-Eleven Biotherapeutics Says Completed Enrollment For Late-Stage Bladder Cancer Study

* ENROLLMENT COMPLETED IN PHASE 3 REGISTRATION TRIAL FOR NON-MUSCLE INVASIVE BLADDER CANCER

BRIEF-Eleven Biotherapeutics Appoints Richard Fitzgerald As CFO

* ELEVEN BIOTHERAPEUTICS APPOINTS RICHARD FITZGERALD AS CHIEF FINANCIAL OFFICER

BRIEF-Eleven Biotherapeutics reports Q3 loss per share $0.37

* Eleven Biotherapeutics reports third quarter 2017 financial results

BRIEF-Eleven Biotherapeutics files for non timely 10-Q

* Eleven biotherapeutics inc files for non timely 10-Q - Sec Filing‍​ Source text: (http://bit.ly/2zZDGkA) Further company coverage:

Select another date: